System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Manon Allaire is an expert in Hepatology at Pitié-Salpêtrière Hospital (France). As of October 2026, ScienceLeadR ranks Manon Allaire in the top 1% of experts worldwide for Liver Neoplasms and Carcinoma. Manon Allaire has authored 168 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 13 of them ongoing. SLR score: 977 (community average: 125). How the SLR is computed.

LeadR Profile

Manon Allaire Pitié-Salpêtrière Hospital France
977 ScienceLeadR Reputation 977

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2015 - 2026
Source: PubMed

Pitié-Salpêtrière Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 168

Citations

Citations: 1 825 1st author: 56 Last author: 22 Unique author: 0

Main journals

J Hepatol 46
Clin Res Hepatol Gastroenterol 16
JHEP Rep 13
Liver Int 9
Hepatology 8

Best Journals

J Hepatol 19
Lancet Gastroenterol Hepatol 2
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).
PMID 42736101 — carcinoma, hepatocellular, safety, neoplasms, drug therapy, tumor burden, chemotherapy		Dig Liver Dis20260
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
PMID 42636832 — carcinoma, hepatocellular, progression-free survival, neoplasms, drug-related side effects and adverse reactions, therapeutics		Lancet Oncol Top journal20260
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.
PMID 42606323 — cells, neoplasms, sorafenib, bevacizumab, immunotherapy, therapeutics		Clin Cancer Res20260
Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).
PMID 42562579 — quality of life, neoplasms, liver, liver neoplasms, ambulatory care, therapeutics		BMJ Open20260
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.
PMID 42330996 — liver diseases, hypertension, carcinoma, hepatocellular, bevacizumab, transaminases, drug-related side effects and adverse reactions, therapeutics, ipilimumab, gastrointestinal diseases		Lancet Gastroenterol Hepatol Top journal20265

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1

By phase:

N/A 10
Phase 2 5
Phase 2/Phase 3 2
Phase 3 2
Phase 1 1

By status:

Recruiting 8
Active not recruiting 5
Completed 5
Not yet recruiting 1
Terminated 1

By type:

Interventional 13
Observational 7

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 1
multicentric5to9 0
multicentricup10 13

Main Topics

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 1b study investigating the association of NP137 with Atezolizumab Bevacizumab combination in first line in unresectable hepatocellular carcinoma
2022-500903-38-00 — carcinoma, hepatocellular, bevacizumab, carcinoma		Phase 1Active not recruiting2023
JAK1 inhibitor treatment of inflammatory liver adenomas
2023-505278-13-00 — estrogens, neoplasms, contraception, liver, adenoma, liver cell, histology, adenoma, therapeutics, male, women		Phase 2Active not recruiting2024
Liver Transplant for Hepatocellular Carcinoma
NCT07629193 — liver transplantation, carcinoma, hepatocellular, liver, transplants, research, therapeutics, transplantation, carcinoma		N/ANot yet recruiting2026
Safety of Atezolizumab Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO TH)
2024-514400-14-00 — carcinoma, hepatocellular, safety, bevacizumab, liver, carcinoma		Phase 2Recruiting2026
TERTIO Evaluation de l int r t de combiner un vaccin inducteur de CD4 Th1 d riv de la t lom rase avec un traitement par atezolizumab et bevacizumab chez des patients avec un carcinome h patocellulaire non r s cable une tude de phase II randomis e preuve du concept
2022-500643-20-00 — carcinoma, hepatocellular, vaccines, neoplasms, telomerase, bevacizumab, cancer vaccines, carcinoma		Phase 2Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS